Abigail Lewis

A recent survey reveals rimegepant's effectiveness for short-term migraine prevention, highlighting user demographics, triggers, and treatment strategies.

As the first FDA-approved treatment for Alzheimer agitation, brexpiprazole showcased effective symptom relief with a favorable safety profile.

A recent survey reveals critical gaps in neurology training on women's health, highlighting the need for urgent curriculum reforms in medical education.

Skyhawk Therapeutics initiates FALCON-HD trial for SKY-0515, a promising treatment for Huntington disease, aiming to modify disease progression.

Richard Bogan, MD, FCCP, FAASM, an associate clinical professor at the University of South Carolina School of Medicine, discussed a bevy of presentations from the 2025 SLEEP Annual Meeting highlighting the effects of once-nightly sodium oxybate.

Marketed as the first drug to target both BLyS and APRIL, Telitacicept may offer a revolutionary treatment option for patients with myasthenia gravis.

The ExTINGUISH trial investigates inebilizumab's efficacy for NMDAR encephalitis, aiming to enhance treatment options for diverse patient populations.